Multimodal silica-based nanoparticles

Patent metadata

Field	Value
Publication number	US-10039847-B2
Application number	US-201715714189-A
Country	US
Kind code	B2
Filing date	Sep 25, 2017
Priority date	Mar 15, 2013
Publication date	Aug 7, 2018
Grant date	Aug 7, 2018

Abstract

The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.

First claim

What is claimed is:

1. A fluorescent silica-based nanoparticle comprising:
a silica-based core;
a fluorescent compound within the core;
a silica shell surrounding at least a portion of the core;
an organic polymer attached to the nanoparticle, thereby coating the nanoparticle; and
a plurality of D-Lys-ReCCMSH-containing peptide ligands no greater than twenty in number attached to the polymer-coated nanoparticle,
wherein the polymer-coated nanoparticles with the ligands attached thereto has a hydrodynamic diameter within a range from 1 nm to 15 nm as measured by dynamic light scattering.

2. The nanoparticle of claim 1 , wherein the organic polymer comprises polyethylene glycol.

3. The nanoparticle of claim 2 , wherein the polyethylene glycol is attached to a silica surface of the nanoparticle via an amino-silane coupled to an activated ester group on the organic polymer leading to an amide bond.

4. The nanoparticle of claim 3 , wherein the nanoparticle is coated with maleimido-terminated polyethylene glycol chains for attachment of the plurality of D-Lys-ReCCMSH peptide ligands.

5. The nanoparticle of claim 1 , wherein each of the plurality of D-Lys-ReCCMSH-containing peptide ligands is attached to the polymer-coated nanoparticle via a N-terminal cysteine thiol.

6. The nanoparticle of claim 5 , wherein a spacer comprising two amino hexanoic acid units separates the polymer-coated nanoparticle and each of the plurality of D-Lys-ReCCMSH peptide ligand.

7. The nanoparticle of claim 1 , wherein a plurality of Lys-ReCCMSH-containing peptide ligands no greater than ten in number are attached to the polymer-coated nanoparticle.

8. The nanoparticle of claim 1 , comprising a radionuclide, wherein each of the plurality of D-Lys-ReCCMSH-containing peptide ligands are labeled with the radionuclide.

9. The nanoparticle of claim 8 , wherein the radionuclide comprises a member selected from the group consisting of 99m Tc, 125 I, 90 Y, 131 I, 177 Lu, and 188 Re.

10. The nanoparticle of claim 8 , wherein each of the plurality of D-Lys-ReCCMSH-containing peptide ligands comprise a free amino group containing side chain for radiolabeling.

11. The nanoparticle of claim 10 , wherein the free amino group containing side chain comprises D-Lysine or an amino group terminated side chain of one or more carbons in length.

12. The nanoparticle of claim 10 , wherein each of the plurality of D-Lys-ReCCMSH-containing peptide ligands are labeled with the radionuclide via a metal chelator appended to the amino terminus of the plurality of D-Lys-ReCCMSH-containing peptide ligands.

13. The nanoparticle of claim 1 , further comprising a therapeutic agent.

14. The nanoparticle of claim 1 , wherein the fluorescent compound is Cy5.

15. The nanoparticle of claim 1 , wherein the fluorescent compound is Cy5.5.

16. The nanoparticle of claim 1 , wherein the plurality of D-Lys-ReCCMSH-containing peptide ligands is a plurality of N-Ac-Cys-(Ahx) 2 -D-Lys-ReCCMSH-containing peptide ligands.

Assignees

• Sloan Kettering Inst Cancer Res
• Univ Cornell
• Univ Missouri

Inventors

• Bradbury Michelle S
• Wiesner Ulrich
• Medina Oula Penate
• Burns Andrew
• Lewis Jason S
• Larson Steven M
• Quinn Thomas P

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• G01N33/575

  for cancer · CPC title

• G01N33/587

  Nanoparticles · CPC title

• A61K49/0002

  General or multifunctional contrast agents, e.g. chelated agents · CPC title

• G01N33/552

  Glass or silica · CPC title